<DOC>
	<DOCNO>NCT00408317</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Ultrase® MT20 compare placebo correction fat protein malabsorption participant cystic fibrosis ( CF ) exocrine pancreatic insufficiency ( EPI ) . This study sponsor Aptalis Pharma ( formerly Axcan ) .</brief_summary>
	<brief_title>Safety Efficacy Study ULTRASE® MT20 Participants With Cystic Fibrosis ( CF ) Exocrine Pancreatic Insufficiency ( PI )</brief_title>
	<detailed_description>This Phase III , multicenter , randomize , double-blind , two-period cross-over , placebo-controlled study design compare efficacy safety Ultrase® MT20 placebo participant CF pancreatic insufficiency . The study consist screen period ( 11 day ) two treatment period ( 6-7 day ) . During screen period participant treat open-label Ultrase® MT18 MT20 . Each treatment period precede stabilization period ( 4 day ) two treatment period separate break period ( 3-6 day ) . A safety follow-up visit perform 7-10 day discharge last treatment period .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Participants legally authorize representative must understand nature study sign inform consent assent form along parental form Participants must confirm diagnosis CF base 1 clinical feature consistent CF phenotype , one following : A genotype 2 identifiable mutation consistent CF A sweat chloride test great 60 millimole per liter ( mmol/L ) quantitative pilocarpine iontophoresis Participants must PI demonstrated fecal elastase1 ( FE1 ) concentration le 100 microgram per gram ( mcg/g ) stool ( ScheBo test ) must require pancreatic enzyme supplementation Participants must clinically stable evidenced medical medication history , baseline physical examination include vital sign laboratory analyse Participants must 7 year old Participants must adequate nutritional status base follow body mass index ( BMI ) : Participants 7 20 year old must BMI great equal fifth percentile Female participant great 20 year old must BMI great equal 16 Male participant great 20 year old must BMI great equal 16.5 Participants must optimal clinical dose pancreatic enzyme ( Ultrase® MT18 MT20 pancreatic enzyme preparation include Ultrase® MT12 ) prior entry study , must tolerate medication opinion investigator Participants must able swallow capsule must able eat high fat diet calculate 2 gram ( ± 15 % ) fat per kilogram body weight per day Participants must , opinion investigator , able willing complete study Female participant must premenarcheal , surgically sterile postmenopausal least 12 consecutive month . Otherwise , woman childbearing potential ( WOCBP ) must pregnant must practice acceptable method contraception least one month prior study entry Participants know contraindication , sensitivity hypersensitivity Ultrase porcine protein Participants know allergy food drug cosmetic ( FD &amp; C ) Blue No . 2 dye indicator ( stool marker ) Participants willing stop prohibit medication product study entry throughout study Participants use narcotic Participants use bowel stimulant and/or laxatives regular basis Participants acute pancreatitis acute exacerbation chronic pancreatic disease Participants acute pulmonary infection Participants history bowel resection Participants suffer dysmotility disorder Participants chronic severe abdominal pain Participants receive enteral tube feed willing stop course study Participants know significant medical disease would compromise welfare confound study result Participants history current diagnosis clinically significant portal hypertension Participants condition know increase fecal fat loss include celiac 's disease , biliary cancer , biliary stricture , cholelithiasis , Crohn 's disease , pancreas cancer , radiation enteritis , tropical sprue , Whipple 's disease , lactose intolerance , pseudomembranous colitis Participants current diagnosis history complete distal intestinal obstruction syndrome ( DIOS ) past 6 month ; , participant 2 episode DIOS past year Participants poorly control diabetes investigator 's opinion Female participant pregnant lactate Participants receive investigational drug within 30 day prior entry study</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Exocrine Pancreatic Insufficiency</keyword>
	<keyword>Ultrase® MT20</keyword>
</DOC>